Despite their side effects, cholinesterase (ChE) inhibitors remain the only approved drugs to treat Alzheimer’s disease patients, along with the N-methyl-d-aspartate (NMDA) receptor antagonist memantine. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.